Chemical Works Of Gedeon Richter Plc · BET:RICHTER
Chemical Works Of Gedeon Richter — Richter Gedeon — Q1 2021 Earnings Presentation
18 slides from Chemical Works Of Gedeon Richter's earnings presentation, May 10, 2021
Slide 1: Richter Group Report, Q1 2021
Richter Group Report, Q1 2021 Budapest, 10 May 2021
Slide 2: Highlights
Report, Q1 2021 Highlights 140,894 HUFm 55.5% Consolidated Gross margin sales -0.4% 17.3% 145 HUF Operating margin EPS -7.1% 26,888 HUFm Net profit* -7.3% * Net income attributable to owners of the parent. 2
Slide 3: Consolidated sales by main business segments
Report, Q1 2021 Consolidated sales -0.4% by main business segments HUF 140,894m HUF 141,426m +7.7% Wholesale and retail -3.9% Pharma Q1 2021 Q1 2020 Pharma W&R 3
Slide 4: Revenue by strategic pillars
Report, Q1 2021 Revenue by strategic pillars (%) Q1 2021 29% 12% 35% 19% 5% Branded Traditionals WHC Cariprazine Biosimilars generics Q1 2020 32% 16% 36% 13% 3% 4
Slide 5: Key products (1/2)
Report, Q1 2021 Key products (1/2) Cariprazine USA - Austria, Kingdom of Saudi HUF 21,487m HUF 20,801m Vraylar® Arabia - Reagila® (EUR 59.3m) royalty income market launch Turnover +37.0% Ongoing phase III clinical trials – MDD adjunctive therapy Central Nervous System Terrosa® Rapid sales growth Sou
Slide 6: Key products (2/2)
Report, Q1 2021 Key products (2/2) Bemfola® HUF 5,255m Improving sales occurred subsequent to fertility centres partially resuming their (EUR 14.5m) activities in many European countries. Nőgyógyászat +10.4% Turnover WHC Evra® HUF 3,373m According to a transitional business licence agreement, royalt
Slide 7: Sales by geographies (%)
Report, Q1 2021 Sales by geographies (%) HUF 112.1bn Q1 2021 23% 10% 33% 22% 12% -3.9% CIS Hungary Europe USA Other global markets* Q1 2020 29% 9% 34% 17% 11% HUF 116.6bn * Including the regions of China, Latin America and Rest of the World. 7
Slide 8: Sales by main regions (HUFm)
Report, Q1 2021 Sales by main HUFm regions (HUFm) -18.0% +26.5% 30 000 25 000 +3.0% 20 000 15 000 +2.2% 10 000 5 000 0 Hungary WEU Russia USA Q1 2021 Q1 2020 (HUFm) Q1 2021 Q1 2020 Change Hungary 11,016 10,781 235 WEU 18,917 18,367 550 Russia 18,165 22,157 -3,992 USA 24,479 19,349 5,130 8
Slide 9: The effects of the COVID-19 pandemic
Report, Q1 2021 The effects of the COVID-19 pandemic Our employees Sales Management Financials ▪ Preserving the health ▪ Decrease in demand ▪ Fluctuations in orders ▪ Solid foundations: of our colleagues due to limitation of capital strength, no ▪ Increase in level of remains our most doctor-patient
Slide 10: Strengths and challenges in key markets
Report, Q1 2021 Strengths and USA Russia challenges in key markets Significant increase in royalty income New submitted prices entering into effect related to the sales of Vraylar® during first half of 2021 Local manufacturers realised higher WEU sales in volume terms compared to declining sales of
Slide 11: Financials – Consolidated Highlights
Report, Q1 2021 Consolidated Financials – Highlights as % of HUFbn Change % EURm total revenues Total revenue 140.9 -0.4 389.0 Gross profit 78.2 -2.5 215.9 55.5 Profit from operations 24.4 -3.2 67.3 17.3 Profit for the period* 26.9 -7.3 74.2 19.1 HUF Change % EUR EPS (diluted) 145 -7.1 0.40 * Net in
Slide 12: Decreasing gross profit and margin
Report, Q1 2021 HUFbn Decreasing 600 62% Significant increase in royalties received gross profit and 500 61% in respect of the sales of Vraylar® (HUF 5,890m) margin (HUFbn) 60% 400 59% Royalty in respect of Evra® has 56,7% 300 58% appeared as a new element 55,5% 57% 200 56% 100 55% 0 54% Declining s
Slide 13: S&M costs (HUFm)
Report, Q1 2021 S&M costs HUFm (HUFm) 140 000 60% 120 000 50% 100 000 40% 80 000 30% 60 000 20% 40 000 10% 20 000 0 0% 2016 2017 2018 2019* 2020* Q1 2020* Q1 2021 S&M costs S&M percentage of sales * Reclassification of depreciation of intangible assets representing sales and other product-related li
Slide 14: R&D costs (HUFm)
Report, Q1 2021 HUFm 60 000 15% R&D costs (HUFm) 50 000 40 000 10% 30 000 20 000 5% 10 000 0 0% 2016 2017 2018 2019 2020 Q1 2020 Q1 2021 R&D costs R&D percentage of sales Split of R&D spending (%) – Q1 2021 CNS original Biosimilars WHC Branded generic research (including and traditional cariprazine)
Slide 15: Decreasing operating profit and margin
Report, Q1 2021 HUFm Decreasing 120 000 25% 17.8% operating profit and Significant Vralyar® royalty 100 000 17.3% margin (HUFm) 20% 80 000 Declining S&M costs 15% 60 000 10% 40 000 5% The share of sales in the pharmaceutical 20 000 segment declined within the Group 0 0% Decrease of gross profit 2016
Slide 16: Factors impacting pharma segment operating profit
Report, Q1 2021 HUFm Increase Decrease Total Factors impacting pharma segment operating profit 16
Slide 17: Corporate matters: Share Ownership Structure
Report, Q1 2021 Corporate matters Share Ownership Structure 31 March 2021 Domestic investors 8% International investors Maecenas 67% Universitatis Corvini 10% Foundation 10% Tihanyi Foundation 5% Hungarian State Holding Company 17
Slide 18: Richter Gedeon
RICHTER GEDEON